According to a new report, published by KBV research, The Global PARP Inhibitor Biomarkers Market size is expected to reach $1.6 billion by 2031, rising at a market growth of 8.3% CAGR during the forecast period.
The Assays segment is anticipating a CAGR of 8.9% during (2024 - 2031). Assays undergo rigorous validation to demonstrate their clinical utility and reliability in predicting treatment response or guiding therapeutic decisions. As biomarker testing becomes increasingly integrated into routine clinical care, there is a growing demand for assays that have been validated for specific biomarker targets and indications associated with PARP inhibitor therapy.
The Breast Cancer segment is leading the Global PARP Inhibitor Biomarkers Market by Application in 2023; thereby, achieving a market value of $735.9 Million by 2031. Breast cancer is one of the cancer types most associated with BRCA1 and BRCA2 mutations, which are well-established biomarkers for PARP inhibitor sensitivity. Therefore, there is a substantial pool of breast cancer patients who may benefit from PARP inhibitor therapy based on their BRCA mutation status, driving the demand for PARP inhibitor biomarkers in this population.
The HRD Testing segment is registering a CAGR of 8.7% during (2024 - 2031). HRD testing is crucial in predicting sensitivity to PARP inhibitors in cancer treatment. Tumours with HRD, which includes deficiencies in DNA repair pathways such as homologous recombination, are more likely to respond to PARP inhibitor therapy. As PARP inhibitors gain wider acceptance as targeted therapies in various cancer types, there is a growing demand for HRD testing to identify patients most likely to benefit from these treatments.
Full Report: https://www.kbvresearch.com/parp-inhibitor-biomarkers-market/
The North America region dominated the Global PARP Inhibitor Biomarkers Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $669.5 Million by 2031. The Europe region is experiencing a CAGR of 8.1% during (2024 - 2031). Additionally, The Asia Pacific region would exhibit a CAGR of 8.9% during (2024 - 2031).
By Product
By Application
By Services
By Geography
Unique Offerings 
